Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations
about
Development of new immunotherapy treatments in different cancer typesT- and NK-cell populations with regulatory phenotype and markers of apoptosis in circulating lymphocytes of patients with CIN3 or microcarcinoma of the cervix: evidence for potential mechanisms of immune suppressionRecent advances in CD8+ regulatory T cell research.
P2860
Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pharmacologic management of ad ...... munotherapeutic considerations
@ast
Pharmacologic management of ad ...... munotherapeutic considerations
@en
Pharmacologic management of ad ...... munotherapeutic considerations
@nl
type
label
Pharmacologic management of ad ...... munotherapeutic considerations
@ast
Pharmacologic management of ad ...... munotherapeutic considerations
@en
Pharmacologic management of ad ...... munotherapeutic considerations
@nl
prefLabel
Pharmacologic management of ad ...... munotherapeutic considerations
@ast
Pharmacologic management of ad ...... munotherapeutic considerations
@en
Pharmacologic management of ad ...... munotherapeutic considerations
@nl
P2860
P1433
P1476
Pharmacologic management of ad ...... munotherapeutic considerations
@en
P2093
Krishnansu S. Tewari
Teresa C. Longoria
P2860
P2888
P304
P356
10.1007/S40265-015-0481-Z
P407
P577
2015-11-01T00:00:00Z
P5875
P6179
1016516746